AR020030A1 - FORMAS CRISTALINAS DE UN ANTIBIoTICO MACRoLIDO; COMPOSICION FARMACÉUTICA Y PROCEDIMIENTO PARA SU PREPARACION. - Google Patents

FORMAS CRISTALINAS DE UN ANTIBIoTICO MACRoLIDO; COMPOSICION FARMACÉUTICA Y PROCEDIMIENTO PARA SU PREPARACION.

Info

Publication number
AR020030A1
AR020030A1 ARP000102353A ARP000102353A AR020030A1 AR 020030 A1 AR020030 A1 AR 020030A1 AR P000102353 A ARP000102353 A AR P000102353A AR P000102353 A ARP000102353 A AR P000102353A AR 020030 A1 AR020030 A1 AR 020030A1
Authority
AR
Argentina
Prior art keywords
preparation
procedure
pharmaceutical composition
crystal forms
antibiotic macrolide
Prior art date
Application number
ARP000102353A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR020030A1 publication Critical patent/AR020030A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen nuevas formas cristalinas de un compuesto de formula 1. También se descriven composiciones farmacéuticas que comprenden estas formas yprocedimientos para su preparacion.
ARP000102353A 1999-05-18 2000-05-16 FORMAS CRISTALINAS DE UN ANTIBIoTICO MACRoLIDO; COMPOSICION FARMACÉUTICA Y PROCEDIMIENTO PARA SU PREPARACION. AR020030A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13464499P 1999-05-18 1999-05-18

Publications (1)

Publication Number Publication Date
AR020030A1 true AR020030A1 (es) 2002-03-27

Family

ID=22464300

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102353A AR020030A1 (es) 1999-05-18 2000-05-16 FORMAS CRISTALINAS DE UN ANTIBIoTICO MACRoLIDO; COMPOSICION FARMACÉUTICA Y PROCEDIMIENTO PARA SU PREPARACION.

Country Status (43)

Country Link
US (1) US6583274B1 (es)
EP (1) EP1189912B1 (es)
JP (1) JP3897983B2 (es)
KR (1) KR100474229B1 (es)
CN (1) CN1203084C (es)
AP (1) AP2001002325A0 (es)
AR (1) AR020030A1 (es)
AT (1) ATE392427T1 (es)
AU (1) AU772283B2 (es)
BG (1) BG106150A (es)
BR (1) BR0011300A (es)
CA (1) CA2372206C (es)
CZ (1) CZ20014120A3 (es)
DE (1) DE60038610T2 (es)
DK (1) DK1189912T3 (es)
DZ (1) DZ3043A1 (es)
EA (1) EA003417B1 (es)
ES (1) ES2302689T3 (es)
GT (1) GT200000072A (es)
HK (1) HK1045521B (es)
HN (1) HN2000000056A (es)
HR (1) HRP20010849A2 (es)
HU (1) HUP0201341A3 (es)
IL (2) IL145946A0 (es)
IS (1) IS6127A (es)
MA (1) MA26735A1 (es)
MX (1) MXPA01011914A (es)
MY (1) MY133397A (es)
NO (1) NO320195B1 (es)
NZ (1) NZ514765A (es)
OA (1) OA11876A (es)
PA (1) PA8495001A1 (es)
PE (1) PE20010151A1 (es)
PL (1) PL353316A1 (es)
PT (1) PT1189912E (es)
SK (1) SK16472001A3 (es)
TN (1) TNSN00103A1 (es)
TW (1) TWI225066B (es)
UA (1) UA67842C2 (es)
UY (1) UY26144A1 (es)
WO (1) WO2000069874A1 (es)
YU (1) YU76601A (es)
ZA (1) ZA200109420B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
MXPA02007305A (es) * 2000-01-27 2002-11-29 Pfizer Prod Inc Composiciones antiboticas de azalida.
JP4104463B2 (ja) * 2001-04-27 2008-06-18 ファイザー・プロダクツ・インク ４’’−置換された−９−デオキソ−９ａ−アザ−９ａ−ホモエリスロマイシン誘導体を製造するための方法
EP1435359A1 (en) * 2002-12-31 2004-07-07 Alembic Limited A process for the purification of roxithromycin
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
TW201038277A (en) * 2009-01-30 2010-11-01 Glaxosmithkline Zagreb Anti-inflammatory macrolide
EP2402355A1 (en) * 2010-07-01 2012-01-04 Novartis AG Crystalline anhydrous forms II and III of Tulathromycin
EP2736915A1 (en) 2011-07-27 2014-06-04 Farma GRS, d.o.o. New crystalline forms of tulathromycin
CN106008622A (zh) * 2016-08-02 2016-10-12 海门慧聚药业有限公司 泰拉霉素新晶型及其制备
CN109942652B (zh) * 2017-12-21 2022-04-26 洛阳惠中兽药有限公司 一种莱柯霉素晶型ⅰ及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.

Also Published As

Publication number Publication date
EP1189912A1 (en) 2002-03-27
GT200000072A (es) 2001-11-08
DE60038610D1 (de) 2008-05-29
TWI225066B (en) 2004-12-11
KR20020007415A (ko) 2002-01-26
CA2372206C (en) 2006-01-10
MXPA01011914A (es) 2002-05-06
IS6127A (is) 2001-10-26
HUP0201341A3 (en) 2003-03-28
DK1189912T3 (da) 2008-06-30
PE20010151A1 (es) 2001-02-08
MY133397A (en) 2007-11-30
BR0011300A (pt) 2002-02-26
YU76601A (sh) 2004-09-03
HUP0201341A2 (en) 2002-08-28
PA8495001A1 (es) 2002-02-21
US6583274B1 (en) 2003-06-24
AU3572900A (en) 2000-12-05
EA200100984A1 (ru) 2002-06-27
NO20015598D0 (no) 2001-11-16
EP1189912B1 (en) 2008-04-16
HK1045521B (zh) 2005-12-09
UY26144A1 (es) 2000-12-29
WO2000069874A1 (en) 2000-11-23
HK1045521A1 (en) 2002-11-29
DZ3043A1 (fr) 2004-03-27
IL145946A0 (en) 2002-07-25
CN1203084C (zh) 2005-05-25
AP2001002325A0 (en) 2001-12-31
TNSN00103A1 (fr) 2005-11-10
ZA200109420B (en) 2002-11-15
EA003417B1 (ru) 2003-04-24
OA11876A (en) 2006-03-27
CN1351607A (zh) 2002-05-29
CZ20014120A3 (cs) 2003-01-15
PL353316A1 (en) 2003-11-17
JP3897983B2 (ja) 2007-03-28
MA26735A1 (fr) 2004-12-20
ATE392427T1 (de) 2008-05-15
HRP20010849A2 (en) 2003-04-30
NO320195B1 (no) 2005-11-14
JP2002544283A (ja) 2002-12-24
CA2372206A1 (en) 2000-11-23
DE60038610T2 (de) 2009-06-25
ES2302689T3 (es) 2008-08-01
HN2000000056A (es) 2001-02-02
AU772283B2 (en) 2004-04-22
IL145946A (en) 2007-06-17
BG106150A (bg) 2002-05-31
UA67842C2 (uk) 2004-07-15
PT1189912E (pt) 2008-05-16
NZ514765A (en) 2004-05-28
KR100474229B1 (ko) 2005-03-08
SK16472001A3 (sk) 2003-02-04
NO20015598L (no) 2002-01-08

Similar Documents

Publication Publication Date Title
TR199901578T2 (xx) Klaritromisin form 0 kristali
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
DK0915898T3 (da) Krystalform I af clarithromycin
AP1422A (en) 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent.
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
YU11997A (sh) Laktamski derivati i njihove farmaceutske kompozicije
CY1107634T1 (el) Φαρμακευτικη συνθεση
NO991494D0 (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
BRPI0213063B8 (pt) composto antibiótico de ação dupla, sua composição farmacêutica e seu uso
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
DE60039238D1 (de) C-2-modifizierte erythromycinderivate
AR020030A1 (es) FORMAS CRISTALINAS DE UN ANTIBIoTICO MACRoLIDO; COMPOSICION FARMACÉUTICA Y PROCEDIMIENTO PARA SU PREPARACION.
MX9300278A (es) Compuestos de arilalcoxifenoxi-imidazolina.
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
BR9503163A (pt) Composição composições farmacêuticas procedimentos para obtenção de composição e para obtenção de quatro subcomposições primeira subcomposição segunda subcomposição terceira subcomposição quarta subcomposição e composição constituída por quatro subcomposições
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
AR022718A1 (es) 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-olessustituidos con n-(5-fenil-tetrahidrofuranil)metilo y n-(6-fenil-tetrahidropiranil)metilo;procedimientos para prepararlos y su empleo como composiciones farmaceuticas.
ES2150151T3 (es) Derivados de 21-(2-oxo-tetrahidrofuran)-tio-pregnano, un procedimiento para su produccion y composiciones farmaceuticas que los contienen.
ES2192870T3 (es) Derivados de benzofurano, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
NO970127L (no) Topiske sammensetninger for behandling av hudsykdom
DK1575969T3 (da) Substituerede 9a-N-(N'-4(sulfonyl)phenylcarbamoyl)-derivater af 9 deoxo-9-dihydro-9a-aza-9a-homoerithromycin A og 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolid A
DE69824410D1 (en) Antithrombosemittel

Legal Events

Date Code Title Description
FC Refusal